Glenmede Trust’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Glenmede Trust’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50	Closed	–	–	2396
2020 Q3	$0	Hold	50	–	–	﹤0.01%	2618
2020 Q2	$0	Hold	50	–	–	﹤0.01%	2666
2020 Q1	$0	Hold	50	–	–	﹤0.01%	3077
2019 Q4	$0	Hold	50	–	–	﹤0.01%	3158
2019 Q3	$0	Hold	50	–	–	﹤0.01%	3154
2019 Q2	$0	Hold	50	–	–	﹤0.01%	3212
2019 Q1	$0	Buy	+50	New	+$243	﹤0.01%	3212
2018 Q2	–	Sell	-250	Closed	-$3K	–	2388
2018 Q1	$3K	Hold	250	–	–	﹤0.01%	2540
2017 Q4	$3K	Sell	250 -300	-55%	-$3.44K	﹤0.01%	2540
2017 Q3	$4K	Buy	550 +50	+10%	+$529	﹤0.01%	2427
2017 Q2	$10K	Hold	500	–	–	﹤0.01%	2129
2017 Q1	$10K	Hold	500	–	–	﹤0.01%	2129
2016 Q4	$7K	Buy	+500	New	+$6.73K	﹤0.01%	2183

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Glenmede Trust's ZYNE Position: Q4 2020 in Review

Glenmede Trust sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2020, closing a stake of 50 shares.

Glenmede Trust first reported a position in ZYNE in Q4 2016 and held it in 13 quarters. The position peaked at $10K in Q2 2017. 58 funds tracked by Wall St. Rank hold ZYNE as of Q4 2020.

Glenmede Trust reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 50 Zynerba Pharmaceuticals, Inc shares in Q4 2020.
Glenmede Trust first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2016 and held it in 13 quarters.
Glenmede Trust's Zynerba Pharmaceuticals, Inc position peaked at $10K in Q2 2017.
58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.